ACLX vs. IMCR, TWST, DNLI, VCEL, KYMR, CGON, APGE, SANA, SWTX, and RXRX
Should you be buying Arcellx stock or one of its competitors? The main competitors of Arcellx include Immunocore (IMCR), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Vericel (VCEL), Kymera Therapeutics (KYMR), CG Oncology (CGON), Apogee Therapeutics (APGE), Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
Arcellx has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Immunocore received 5 more outperform votes than Arcellx when rated by MarketBeat users. However, 75.00% of users gave Arcellx an outperform vote while only 70.15% of users gave Immunocore an outperform vote.
Immunocore has higher revenue and earnings than Arcellx. Immunocore is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks.
Arcellx presently has a consensus target price of $78.20, indicating a potential upside of 57.22%. Immunocore has a consensus target price of $82.00, indicating a potential upside of 39.10%. Given Arcellx's stronger consensus rating and higher possible upside, analysts plainly believe Arcellx is more favorable than Immunocore.
Immunocore has a net margin of -22.60% compared to Arcellx's net margin of -38.39%. Arcellx's return on equity of -14.51% beat Immunocore's return on equity.
In the previous week, Immunocore had 1 more articles in the media than Arcellx. MarketBeat recorded 24 mentions for Immunocore and 23 mentions for Arcellx. Arcellx's average media sentiment score of 0.59 beat Immunocore's score of 0.21 indicating that Arcellx is being referred to more favorably in the media.
96.0% of Arcellx shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 6.2% of Arcellx shares are owned by company insiders. Comparatively, 9.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Arcellx beats Immunocore on 10 of the 18 factors compared between the two stocks.
Get Arcellx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
